MedTrace Logo

Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure

NCT03709160 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-10-17

No results posted yet for this study

Summary

In the present study, consecutive patients, older than 18 years, of both genders will be included. The diagnosis of reduced Heart Failure (HfrEF) according to: Clinical pattern, laboratories and Cardiac imaging (ESC criteria). Treatment will be assigned in two groups: Bumetanide and another group will be received Indapamide. Each group received maximum tolerated dose for seven days with Clinical and labs evaluations will be every 48 hrs. (Face-to-face and/or telephone visits). Serum and urinary labs, EKG´s, Echo will be evaluated. Daily in-home register will made. Final points were: Mortality, Urinary failure, Clinical Impairment, Hospital admissions, Oedema. (MUCHO). All patients will be followed for 30 days.

Conditions

Interventions

DRUG

Bumetanide 1 MG

all patients will be taking the treatment recommended by heart failure guidelines

Sponsors & Collaborators

  • Centro en Insuficiencia Cardiaca, Mexico

    lead OTHER

Principal Investigators

  • EDUARDO CHUQUIURE-VALENZUELA, MD MSc · HEART FAILURE CENTER INSTITUTO NACIONAL DE CARDIOLOGIA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2019-10-15
Completion
2019-10-15

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709160 on ClinicalTrials.gov